Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025

Dermata Therapeutics, Inc.

Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.
Topline data from STAR-2 expected H1 2027; patients can rollover into 9-month extension study.
NDA filing for XYNGARI anticipated in H1 2028 after extension study completion by end of Q4 2027.

item 7.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.